CGM

Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference

Retrieved on: 
星期三, 三月 6, 2024
Health, Communications, Medical Devices, Diabetes, Health Technology, General Health, Public Relations, Investor Relations, Interest, CGM, Medtech, Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
  • Management is scheduled to participate on Wednesday, March 13, 2024, at 12:00pm ET and will hold one-on-one meetings following.
  • Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com .

Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

Retrieved on: 
星期三, 三月 6, 2024
Technology, General Health, Health, Hardware, MARD, American Diabetes Association, Algorithm, CGM, Know Labs, Treatment, FDA, Blood, Dielectric spectroscopy, Data, Conference, Type 2 diabetes, ATTD, Type 2, Mayo Clinic, Clinical professor, Prediabetes, Clinical trial, RF, CWD, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.
  • Dr. Virend K. Somers of the Mayo Clinic serves as an author and co-investigator on the clinical research protocol.
  • “Despite significant efforts in the development of non-invasive blood glucose monitoring solutions, delivering a highly accurate, economical, FDA-cleared non-invasive continuous glucose monitor (CGM) still remains to be seen.
  • On the held-out test dataset, blood glucose was estimated with a MARD of 11.1 ± 2.1% relative to venous blood.

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Retrieved on: 
星期二, 三月 5, 2024
Software, Health, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, Clinical Trials, Tandem, HCP, CGM, Apple Watch, G6, Diabetic ketoacidosis, AID, DXCM, G7, Hypoglycemia, GLP1, Conference, Type 2 diabetes, ATTD, Type 2, Patient, Insulin, Apple, Mortality, Pharmaceutical industry

Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.

Key Points: 
  • Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.
  • Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.
  • Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023.
  • Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024.

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
星期二, 三月 5, 2024
Health Technology, Diabetes, Manufacturing, Technology, Pharmaceutical, Other Consumer, General Health, Medical Devices, Clinical Trials, Wearables, Mobile Technology, Other Manufacturing, Science, Consumer, Health, Research, Real-World Evidence, Cloud, OBE, Adolescence, Doctor of Philosophy, Treatment, Medical director, Database, University, Hypoglycemia, Associate, AID, University of Liverpool, Standard of care, Data, Therapy, Insulin, Convention, Randomized controlled trial, CGM, Pathway, Use, Conference, MDI, Automation, Endocrinology, MD, DASH, ATTD, Medicare, University of Edinburgh, Edge Hill University, Corporation, Chairperson, Medical device

“We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.

Key Points: 
  • “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
  • It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
  • This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
  • Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Retrieved on: 
星期二, 三月 5, 2024
Software, Health, FDA, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, CGM, Continuity, Multimedia, MD, DXCM, A1C, Type 2 diabetes, Stelo, Type 2, Smartphone, Insulin, Glucose, Insurance, Dietary supplement

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.
  • There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology.
  • Today, Dexcom G7 is available for them with a prescription.
  • To learn more about Stelo and do a benefits check to see if you’re eligible to get started now with Dexcom G7, visit https://www.dexcom.com/en-us/stelo .

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期四, 二月 29, 2024
Diabetes, Health, Medical Devices, Total, Research, CGM, Doctor of Philosophy, Investment, Telephone, Marketing, FDA, Growth, PHC, Conference, Medicare, Patient, Data analysis, Acceleration, Clinical trial, Eastern Time Zone, UnitedHealth Group, Pharmaceutical industry

U.S. revenue was $6.1 million in the fourth quarter of 2023 compared to $3.6 million in the prior year period, and revenue outside the U.S. was $1.9 million in the fourth quarter of 2023 compared to $2.0 million in the prior year period.

Key Points: 
  • U.S. revenue was $6.1 million in the fourth quarter of 2023 compared to $3.6 million in the prior year period, and revenue outside the U.S. was $1.9 million in the fourth quarter of 2023 compared to $2.0 million in the prior year period.
  • Fourth quarter 2023 gross profit of $1.1 million increased from $0.6 million for the fourth quarter of 2022.
  • Fourth quarter 2023 sales and marketing and general and administrative expenses decreased by $0.5 million year-over-year, to $7.3 million.
  • Fourth quarter 2023 research and development expenses decreased by $0.9 million year-over-year, to $10.7 million.

Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor

Retrieved on: 
星期二, 二月 27, 2024
Consumer Electronics, Technology, Diabetes, Health, General Health, Wearables, Mobile Technology, Health Technology, Medical Devices, Research, Science, Hardware, Algorithm, Know Labs, CGM, Multimedia, FDA, Quality of life, Dielectric spectroscopy, Data collection, Prevalence, IP, Glucose, RF, Wrist, Forearm, Medical device

Know Labs , Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM).

Key Points: 
  • Know Labs , Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM).
  • The KnowU brings Know Labs closer to delivering the world’s first non-invasive blood glucose monitor to the global marketplace.
  • It records voltage values detected at each frequency to quantify, with trade-secret machine learning algorithms, real-time continuous blood glucose levels.
  • During 2024, Know Labs will deploy the KnowU in large-scale, external clinical trials while making refinements to the device and its algorithms.

New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management

Retrieved on: 
星期六, 三月 9, 2024
TIR, TITR, CGM, MD, Medtronic, AID, Cohort (statistics), Conference, ATTD, Health, Endocrinology, Therapy, DCCT

DUBLIN and FLORENCE, Italy, March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States. The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy. These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.

Key Points: 
  • The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy.
  • These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.
  • In an oral presentation, Dr. James Thrasher, MD, Founder, Arkansas Diabetes and Endocrinology Center, shared data on early real-world users with type 1 diabetes of the MiniMed™ 780G system in the U.S. (n=7,499).
  • This data reinforces that the determinant of choice for AID systems should be first and foremost the power of the algorithm."

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Retrieved on: 
星期三, 三月 6, 2024
CGM, Blood, Glucose meter, Treatment, Weight loss, Glycated hemoglobin, Food, Conference, Behavior, Type 2 diabetes, ATTD, Type 2, Smartphone, Patient, Insulin, Heart, Continuous glucose monitor, Appetite, Pharmaceutical industry

These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.

Key Points: 
  • These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.
  • GLP-1 medicines – also known as glucagon-like peptide-1 receptor agonist (GLP-1 RA) - are increasingly being prescribed for people with Type 2 diabetes as they provide glycemic benefit and support weight loss.
  • "While treating my patients, I've observed that when we've added a CGM, like the FreeStyle Libre technology, to their GLP-1 therapy, we see even better glycemic control.
  • To maximize the benefits of GLP-1 medicines, it's worth considering the combination of a CGM to support people who live with Type 2 diabetes."

FDA Clears First Over-the-Counter Continuous Glucose Monitor

Retrieved on: 
星期二, 三月 5, 2024
Human services, Diabetes, Dexcom, CGM, Cosmetics, Multimedia, Diet, Dietary supplement, Marketing, FDA, OTC, CDRH, Food, Pain, Exercise, Vaccine, Animal, Health, Infection, Safety, Heated tobacco product, Public, Patient, Insulin, Device, Health equity, Trial of the century, Irritation

SILVER SPRING, Md., March 5, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM).

Key Points: 
  • SILVER SPRING, Md., March 5, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM).
  • "CGMs can be a powerful tool to help monitor blood glucose.
  • The device presents blood glucose measurements and trends every 15 minutes in the accompanying app.
  • Data from a clinical study provided to the FDA showed that the device performed similarly to other iCGMs.